View
212
Download
0
Embed Size (px)
Citation preview
Inpharma 1242 - 17 Jun 2000
Indirect costs lower with raltitrexedPatients’ travel and time costs are significantly lower
for those receiving raltitrexed for the treatment ofadvanced colorectal cancer than for those receivingfluorouracil plus folinic acid [leucovorin], reportresearchers in the UK.*
Their calculations revealed that the total median per-patient cost was £206 for raltitrexed recipients and £342for patients who received fluorouracil plus folinic acid.The respective mean costs per patient were £378 and£486. The researchers comment that this costdifferential is largely due to fewer hospital visits requiredby raltitrexed recipients who receive treatment onceevery 21 days, compared with fluorouracil plus folinicacid recipients who are treated more frequently.
The cost estimates are based on data collectedprospectively from 270 patients who participated in aninternational clinical study;** included were the costs oftravel to and from hospital and time away from usualactivities for treatment administration and the treatmentof adverse events.* The study was funded by AstraZeneca Pharmaceuticals.** In this study, patients were randomised to receive either raltitrexed3 mg/m2 as a 15-minute infusion once every 3 weeks, or fluorouracil400 mg/m2 as a 15-minute infusion plus folinic acid 200 mg/m2/day for5 days every 4 weeks (Machover regimen).
Sculpher M, et al. Costs incurred by patients in advanced colorectal cancertherapy: a comparison of raltitrexed and fluorouracil plus leucovorin.PharmacoEconomics 17: 361-370, Apr 2000 800810316
1
Inpharma 17 Jun 2000 No. 12421173-8324/10/1242-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved